These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 5004500)

  • 1. [State of resistance to rifampicin and other minor antibiotics and bacteriostatic agents in Turkey].
    Gürsel A; Gürdağ G; Atay N; Biçen E
    Turk Hij Tecr Biyol Derg (1961); 1971; 31(2):136-52. PubMed ID: 5004500
    [No Abstract]   [Full Text] [Related]  

  • 2. [In vitro activities of rifabutine and rifampicin against various mycobacteria, especially Mycobacterium tuberculosis and Mycobacterium avium complex].
    Saito H; Sato K; Tomioka H
    Kekkaku; 1988 Mar; 63(3):167-72. PubMed ID: 2836649
    [No Abstract]   [Full Text] [Related]  

  • 3. High initial and acquired drug resistance in pulmonary tuberculosis in Turkey.
    Tahaoğlu K; Kizkin O; Karagöz T; Tor M; Partal M; Sadoğlu T
    Tuber Lung Dis; 1994 Oct; 75(5):324-8. PubMed ID: 7841424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Sensitivity of M. tuberculosis and atypical mycobacteria to ethambutol, capreomycin and rifampicin].
    Schröder KH; Hensel J; Scheuch V
    Prax Pneumol; 1969 Oct; 23(10):683-94. PubMed ID: 4984409
    [No Abstract]   [Full Text] [Related]  

  • 5. [Emergent strains of rifampicin-resistant Mycobacterium tuberculosis complex and susceptibility to isoniazid].
    Cacho-Calvo J; Martín-Díaz A;
    Enferm Infecc Microbiol Clin; 2013; 31(7):486-7. PubMed ID: 23623580
    [No Abstract]   [Full Text] [Related]  

  • 6. [An investigation on multiple drug resistance of the rifampin resistant strains of Mycobacterium tuberculosis].
    Kuang T; Jin G; Song P; Li W; Wang Z
    Wei Sheng Wu Xue Bao; 1998 Apr; 38(2):152-4. PubMed ID: 12549378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Primary resistance of Mycobacterium tuberculosis in the province of Vizcaya].
    Echeverría MJ; Ayarza R; Jiménez MS; López de Goicoechea MJ; Berdonces P; Ibarretxebea AB
    Rev Esp Quimioter; 1999 Jun; 12(2):152-3. PubMed ID: 10562678
    [No Abstract]   [Full Text] [Related]  

  • 8. [Study of primary resistance to antitubercular agents in the Sousse region, 1981-1990].
    Benzarti M; Garrouche A; Jerray M; Hayouni A; Maalel K; Klabi N
    Tunis Med; 1996 Jan; 74(1):23-7. PubMed ID: 9507309
    [No Abstract]   [Full Text] [Related]  

  • 9. Mutations outside the rifampicin resistance-determining region associated with rifampicin resistance in Mycobacterium tuberculosis.
    Siu GK; Zhang Y; Lau TC; Lau RW; Ho PL; Yew WW; Tsui SK; Cheng VC; Yuen KY; Yam WC
    J Antimicrob Chemother; 2011 Apr; 66(4):730-3. PubMed ID: 21393153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Interaction of antitubercular agents. I. Combined action of rifampicin, isonicotinic acid hydrazide, streptomycin and para-aminosalicylic acid on the growth of strains of tubercle bacilli].
    Janowiec M; Zwolska-Kwiek Z; Wiśniewska A; Wróblewska H
    Pneumonol Pol; 1977 Jun; 45(6):425-30. PubMed ID: 406600
    [No Abstract]   [Full Text] [Related]  

  • 11. [Resistance to antitubercular drugs in Chile].
    Valenzuela MT; Scheel G; Ponce J; Lepe R; Velasco M; Valenzuela P
    Rev Med Chil; 1984 Jan; 112(1):76-80. PubMed ID: 6429808
    [No Abstract]   [Full Text] [Related]  

  • 12. Mycobacterium tuberculosis drug resistance: a call to action.
    Sudre P; Cohn DL
    Int J Tuberc Lung Dis; 1998 Aug; 2(8):609-11. PubMed ID: 9712272
    [No Abstract]   [Full Text] [Related]  

  • 13. Comment on: isoniazid and rifampicin resistance-associated mutations in Mycobacterium tuberculosis isolates from Yangon, Myanmar: implications for rapid molecular testing.
    Köser CU; Summers DK; Archer JA
    J Antimicrob Chemother; 2011 Mar; 66(3):686-7; author reply 687. PubMed ID: 21177677
    [No Abstract]   [Full Text] [Related]  

  • 14. [The resistance rates of Mycobacterium tuberculosis strains to antituberculosis drugs: evaluation of two years' data in Aegean region, Turkey].
    Güneri S; Unsal I; Oztop A; Erkut M; Avkan Oğuz V; Ozgü A; Cakmak R
    Mikrobiyol Bul; 2004 Jul; 38(3):203-12. PubMed ID: 15490839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bacteriostatic effect of rifampicin (Rifampin) on Mycobacterium tuberculosis in vitro].
    Woźniak S; Tomaszkiewicz L; Zierski M
    Gruzlica; 1969 Nov; 37(11):983-9. PubMed ID: 4983868
    [No Abstract]   [Full Text] [Related]  

  • 16. Mutant prevention concentration of isoniazid, rifampicin and rifabutin against Mycobacterium tuberculosis.
    Rodríguez JC; Cebrián L; Ruiz M; López M; Royo G
    Chemotherapy; 2005 May; 51(2-3):76-9. PubMed ID: 15870500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of and treatment protocol for rifampicin-monoresistant tuberculosis: what is the role of isoniazid?
    Velayati AA; Farnia P; Masjedi MR; Hoffner S
    Int J Tuberc Lung Dis; 2013 Jun; 17(6):849-50. PubMed ID: 23676176
    [No Abstract]   [Full Text] [Related]  

  • 18. The "in vitro" activity of rifampicin compared with ethambutol, capreomycin and isoniazid.
    Steinbrück PW
    Acta Tuberc Pneumol Belg; 1969; 60(3):413-6. PubMed ID: 4984421
    [No Abstract]   [Full Text] [Related]  

  • 19. Primary drug resistance to Mycobacterium tuberculosis in renal transplant recipients.
    John GT; Mukundan U; Vincent L; Jacob CK; Shastry JC
    Natl Med J India; 1995; 8(5):211-2. PubMed ID: 7549851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quinonoid and phenazine compounds: synthesis and evaluation against H37Rv, rifampicin and isoniazid-resistance strains of Mycobacterium tuberculosis.
    Carneiro PF; Pinto Mdo C; Coelho TS; Cavalcanti BC; Pessoa C; de Simone CA; Nunes IK; de Oliveira NM; de Almeida RG; Pinto AV; de Moura KC; da Silva PA; da Silva Júnior EN
    Eur J Med Chem; 2011 Sep; 46(9):4521-9. PubMed ID: 21820768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.